BUZZ-Cardiff Oncology rises on positive results from mid-stage cancer study

Reuters12-10

** Shares of drug developer Cardiff Oncology rise 33.2% to $3.25 premarket

** Co announces positive initial data from its mid-stage trial testing its experimental cancer drug, onvansertib, in combination with standard-of-care treatment in patients with a type of colorectal cancer

** Co says the combination treatment showed a 64% objective response rate $(ORR.AU)$ in patients who were dosed with 30 mg of the drug vs a 33% ORR in patients who received standard of care alone

** ORR is the proportion of patients whose tumors reduced in size or disappeared over a predefined amount of time

** Co says 30 mg dose demonstrated a higher ORR compared to 20 mg dose, with deeper tumor reduction in patients who received the 30 mg dose

** The drug was well-tolerated and there have been no major or unexpected toxicities observed - CRDF

** Co says additional clinical data is expected in the first half of 2025

** Up to last close, stock up 64.9% YTD

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment